Barreling into March 2025 and as states start to pull together their own budgets, Colorado is not the only state considering pulling back or in some way limiting their coverage either through state employee health plans or in Medicaid of GLP-1s for treating obesity
Nature Reviews Gastroenterology & Hepatology
And with employer-sponsored health costs expected to reach their highest point in a decade in 2025 due in part to coverage of pricey drugs such as GLP-1s businesses are grappling with how to manage costs while meeting employee needs
The anti-inflammatory effects of GLP-1 agonists could potentially help counteract this modern environmental challenge
Hynes RO (1992) Integrins: versatility, modulation, and signaling in cell adhesion
Improving Cognitive Function with Nutritional Supplements in Aging: A Comprehensive Narrative Review of Clinical Studies Investigating the Effects of Vitamins, Minerals, Antioxidants, and Other Dietary Supplements